MA27475A1 - Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase - Google Patents
Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesteraseInfo
- Publication number
- MA27475A1 MA27475A1 MA28224A MA28224A MA27475A1 MA 27475 A1 MA27475 A1 MA 27475A1 MA 28224 A MA28224 A MA 28224A MA 28224 A MA28224 A MA 28224A MA 27475 A1 MA27475 A1 MA 27475A1
- Authority
- MA
- Morocco
- Prior art keywords
- sub
- sup
- optionally substituted
- formula
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un composé de la formule (I) ou bien un sel de celui-ci, dans laquelle R1 représente alkyle C1-4, fluoroalkyle C1-3, -CH2CH2OH ou -CH2CH2CO2 alkyle C1-2;R2 représente un atome d'hydrogène (H), méthyle ou fluoroalkyle C1;R3 représente cycloalkyle C3-8 facultativement substitué ou cycloalcényle C1-7 facultativement substitué mono-insaturé ou un groupe hétérocyclique facultativement substitué de sous-formule (aa), (bb) ou (cc); dans lesquelles n1 et n2 représentent indépendamment 1 ou 2, et dans lesquelles Y représente O, S, SO2, ou NR10; ou R3 représente un groupe bicyclique (dd) ou (ee); et dans laquelle X représente NR4R5 ou OR5a. Les composés sont des inhibiteurs de phosphodiestérase (PDE), en particulier des inhibiteurs de PDE4. L'invention concerne également l'utilisation d'un composé de la formule (I), ou d'un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'un médicament destiné au traitement et/ou à la prophylaxie d'une maladie inflammatoire et/ou allergique chez un mammifère tel que l'homme, par exemple la bronchopneumopathie chronique obstructive (PBCO), l'asthme ou la rhinite allergique.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221455A GB0221455D0 (en) | 2002-09-16 | 2002-09-16 | Compounds |
GBGB0230045.7A GB0230045D0 (en) | 2002-12-23 | 2002-12-23 | Compounds |
GB0306595A GB0306595D0 (en) | 2003-03-21 | 2003-03-21 | Compounds |
GB0308017A GB0308017D0 (en) | 2003-04-07 | 2003-04-07 | Compounds |
GB0319708A GB0319708D0 (en) | 2003-08-21 | 2003-08-21 | Compounds |
GB0321074A GB0321074D0 (en) | 2003-09-09 | 2003-09-09 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27475A1 true MA27475A1 (fr) | 2005-08-01 |
Family
ID=31999797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28224A MA27475A1 (fr) | 2002-09-16 | 2005-04-15 | Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060089375A1 (fr) |
EP (1) | EP1539753B1 (fr) |
JP (1) | JP2006503108A (fr) |
KR (1) | KR20050052501A (fr) |
CN (1) | CN100387598C (fr) |
AT (1) | ATE442367T1 (fr) |
AU (1) | AU2010201417A1 (fr) |
BR (1) | BR0314392A (fr) |
CA (1) | CA2497550A1 (fr) |
CY (1) | CY1109619T1 (fr) |
DE (1) | DE60329193D1 (fr) |
DK (1) | DK1539753T3 (fr) |
ES (1) | ES2331119T3 (fr) |
IL (1) | IL166898A (fr) |
IS (1) | IS7709A (fr) |
MA (1) | MA27475A1 (fr) |
MX (1) | MXPA05002887A (fr) |
NO (1) | NO20050841L (fr) |
NZ (1) | NZ538515A (fr) |
PL (1) | PL375993A1 (fr) |
PT (1) | PT1539753E (fr) |
SI (1) | SI1539753T1 (fr) |
WO (1) | WO2004024728A2 (fr) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
EP1608652A1 (fr) * | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Composes pyrazolopyrimidines et leur utilisation en medecine |
AU2004233827B2 (en) * | 2003-04-24 | 2009-05-28 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
CA2557004A1 (fr) * | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase |
WO2005090352A1 (fr) * | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Compose de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 |
GB0405933D0 (en) * | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
WO2005095328A1 (fr) | 2004-04-02 | 2005-10-13 | Glaxo Group Limited | Processus chimique et nouvelle forme cristalline |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US7459451B2 (en) * | 2004-07-05 | 2008-12-02 | Astellas Pharma Inc. | Pyrazolopyridine derivatives |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP1940836A1 (fr) * | 2005-09-29 | 2008-07-09 | Glaxo Group Limited | Compose de pyrazolo[3,4-b]pyridine et utilisation en tant qu'inhibiteur de pde4 |
AR058109A1 (es) | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie |
CA2644069A1 (fr) | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Piperazines therapeutiques utilisees comme inhibiteurs de la pde4 |
US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
US7723330B2 (en) * | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
KR20090003349A (ko) | 2006-04-20 | 2009-01-09 | 글락소 그룹 리미티드 | 화합물 |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
TW200817006A (en) | 2006-06-23 | 2008-04-16 | Smithkline Beecham Corp | IL-8 receptor antagonist |
DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
WO2009041591A1 (fr) * | 2007-09-28 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | Dérivé de pyridine fusionnée |
EP2070929A1 (fr) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci |
UY31637A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
UY31636A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
CL2009000248A1 (es) * | 2008-02-06 | 2009-09-11 | Glaxo Group Ltd | Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas |
AU2009325091A1 (en) | 2008-05-23 | 2010-06-17 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein inhibitor |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
WO2010094643A1 (fr) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Dérivés de quinoline et applications associées dans la rhinite et l'urticaire |
ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
EP2408769A1 (fr) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Dérivés de pyrimidine utilisés comme inhibiteurs de ltk |
EA201171144A1 (ru) | 2009-03-19 | 2012-04-30 | Мерк Шарп Энд Домэ Корп. | ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
WO2010107958A1 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2411517A2 (fr) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Inhibition à médiation par l'interférence arn de l'expression du gène de la molécule d'adhésion intercellulaire 1 (icam-1) faisant appel à de courts acides nucléiques interférents (ansi) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
WO2010111464A1 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
WO2010122088A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac |
UY32571A (es) | 2009-04-24 | 2010-11-30 | Glaxo Group Ltd | Compuestos derivados de pirazol amida |
SI2899191T1 (sl) | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji |
EP2507223A1 (fr) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
EP2512438B1 (fr) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations et procédés pour le réglage de l'administration de particules d'une certaine taille dans un aérosol-doseur |
WO2011110575A1 (fr) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
EP2397482A1 (fr) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK |
EP2593434A1 (fr) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Composés pyridines comme bloqueurs des canaux sodiques |
ES2602972T3 (es) | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
EP2614058B1 (fr) | 2010-09-08 | 2015-07-08 | GlaxoSmithKline Intellectual Property Development Limited | Polymorphes et sels de n-[5-[4-(5-{[(2r,6s-2,6-diméthyl-4-morpholinyl]- méthyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(méthyloxy)-3-pyridinyl]-méthanesulfonamide |
WO2012035055A1 (fr) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Nouveaux composés |
ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
EP2630127A1 (fr) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Composés de pyrazole agissant contre des troubles allergiques, inflammatoires et immunitaires |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
EP2527344A1 (fr) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires |
US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
WO2015055691A1 (fr) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteur de pi3k pour le traitement d'une maladie respiratoire |
ES2871027T3 (es) * | 2014-03-27 | 2021-10-28 | Eicosis Llc | Inhibidores potentes de la epóxido hidrolasa soluble |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
CR20160529A (es) | 2014-05-12 | 2017-01-02 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones farmacéuticas para tratar enfermedades infecciosas |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
WO2016181990A1 (fr) | 2015-05-12 | 2016-11-17 | 大鵬薬品工業株式会社 | Cristaux de composé azabicyclique |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP2019524792A (ja) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
CN107964011A (zh) * | 2016-10-19 | 2018-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代吡唑并吡啶类衍生物及其医药用途 |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11512067B2 (en) | 2017-09-14 | 2022-11-29 | Daiichi Sankyo Company, Limited | Compound having cyclic structure |
US11505559B2 (en) | 2017-10-30 | 2022-11-22 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors |
US11434247B1 (en) * | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
CN116507336A (zh) | 2020-09-10 | 2023-07-28 | Vanda制药公司 | 治疗pdeiv介导的疾病或病症的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US598973A (en) * | 1898-02-15 | Water-heater and smoke-consumer | ||
US598838A (en) * | 1898-02-08 | William b | ||
US3856799A (en) * | 1971-08-05 | 1974-12-24 | Squibb & Sons Inc | Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters |
BE787249A (fr) * | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
US3833594A (en) * | 1971-08-05 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxylic acids and esters |
US3925388A (en) * | 1971-08-05 | 1975-12-09 | Squibb & Sons Inc | 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters |
US4012373A (en) * | 1972-09-22 | 1977-03-15 | E. R. Squibb & Sons, Inc. | Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones |
US3979399A (en) * | 1972-11-15 | 1976-09-07 | E. R. Squibb & Sons, Inc. | Amino derivatives of pyrazolopyridine carboxamides |
US3840546A (en) * | 1972-11-15 | 1974-10-08 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxamides |
US3833598A (en) * | 1972-12-29 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters |
US4115394A (en) * | 1974-05-06 | 1978-09-19 | E. R. Squibb & Sons, Inc. | Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
CN100387598C (zh) * | 2002-09-16 | 2008-05-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
CA2557004A1 (fr) * | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase |
-
2003
- 2003-09-12 CN CNB038250438A patent/CN100387598C/zh not_active Expired - Fee Related
- 2003-09-12 PT PT03778283T patent/PT1539753E/pt unknown
- 2003-09-12 US US10/527,866 patent/US20060089375A1/en not_active Abandoned
- 2003-09-12 ES ES03778283T patent/ES2331119T3/es not_active Expired - Lifetime
- 2003-09-12 WO PCT/EP2003/011814 patent/WO2004024728A2/fr active Application Filing
- 2003-09-12 AT AT03778283T patent/ATE442367T1/de active
- 2003-09-12 NZ NZ538515A patent/NZ538515A/en unknown
- 2003-09-12 PL PL03375993A patent/PL375993A1/xx not_active Application Discontinuation
- 2003-09-12 EP EP03778283A patent/EP1539753B1/fr not_active Expired - Lifetime
- 2003-09-12 MX MXPA05002887A patent/MXPA05002887A/es active IP Right Grant
- 2003-09-12 BR BR0314392-9A patent/BR0314392A/pt not_active IP Right Cessation
- 2003-09-12 CA CA002497550A patent/CA2497550A1/fr not_active Abandoned
- 2003-09-12 DE DE60329193T patent/DE60329193D1/de not_active Expired - Lifetime
- 2003-09-12 KR KR1020057004514A patent/KR20050052501A/ko not_active Application Discontinuation
- 2003-09-12 DK DK03778283T patent/DK1539753T3/da active
- 2003-09-12 SI SI200331680T patent/SI1539753T1/sl unknown
- 2003-09-12 JP JP2004571743A patent/JP2006503108A/ja active Pending
-
2005
- 2005-02-15 IL IL166898A patent/IL166898A/en not_active IP Right Cessation
- 2005-02-16 NO NO20050841A patent/NO20050841L/no unknown
- 2005-02-24 IS IS7709A patent/IS7709A/is unknown
- 2005-04-15 MA MA28224A patent/MA27475A1/fr unknown
-
2008
- 2008-01-14 US US12/013,529 patent/US20080175914A1/en not_active Abandoned
-
2009
- 2009-11-24 CY CY20091101212T patent/CY1109619T1/el unknown
-
2010
- 2010-04-08 AU AU2010201417A patent/AU2010201417A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20050841L (no) | 2005-06-15 |
CY1109619T1 (el) | 2014-08-13 |
JP2006503108A (ja) | 2006-01-26 |
PL375993A1 (en) | 2005-12-12 |
BR0314392A (pt) | 2005-07-12 |
WO2004024728A3 (fr) | 2004-10-21 |
EP1539753B1 (fr) | 2009-09-09 |
NZ538515A (en) | 2007-04-27 |
PT1539753E (pt) | 2009-12-10 |
CN100387598C (zh) | 2008-05-14 |
DK1539753T3 (da) | 2010-01-04 |
EP1539753A2 (fr) | 2005-06-15 |
MXPA05002887A (es) | 2005-05-27 |
KR20050052501A (ko) | 2005-06-02 |
ATE442367T1 (de) | 2009-09-15 |
SI1539753T1 (sl) | 2009-12-31 |
DE60329193D1 (de) | 2009-10-22 |
WO2004024728A2 (fr) | 2004-03-25 |
ES2331119T3 (es) | 2009-12-22 |
CN1694882A (zh) | 2005-11-09 |
US20060089375A1 (en) | 2006-04-27 |
IL166898A (en) | 2010-06-30 |
US20080175914A1 (en) | 2008-07-24 |
AU2010201417A1 (en) | 2010-04-29 |
AU2003285300A1 (en) | 2004-04-30 |
CA2497550A1 (fr) | 2004-03-25 |
IS7709A (is) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27475A1 (fr) | Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase | |
TW200500364A (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | |
KR100313641B1 (ko) | 6-페닐피리딜-2-아민유도체 | |
NO20063340L (no) | Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer | |
JP2013530179A (ja) | 呼吸器合胞体ウイルス(rsv)感染の処置に使用するためのウレイド−ピラゾール誘導体 | |
WO2007040438A3 (fr) | Derives d'imidazo(4,5-b) pyridine utilises comme inhibiteurs de la glycogene synthase kinase 3 pour le traitement de la demence et de troubles neurodegeneratifs | |
GEP20104973B (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
WO2007039781A3 (fr) | Nouveaux composes | |
WO2006011024A3 (fr) | Nouveaux composes tricycliques utilises dans le traitement de troubles inflammatoires et allergiques, procede de preparation associe, et compositions pharmaceutiques les contenant | |
KR20180128390A (ko) | 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도 | |
KR20180004817A (ko) | 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도 | |
ID27509A (id) | Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya | |
RU2009109100A (ru) | НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2(3Н)-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
WO2016138199A1 (fr) | Composés benzothiophène et benzothiazole | |
RU2012131280A (ru) | [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез | |
MX2012008147A (es) | Derivados de pirrazolopiridina. | |
CA2837248A1 (fr) | Nouveaux derives de phtalazinone -pyrrolopyrimidinecarboxamide | |
CN106065018B (zh) | 取代的吲哚化合物及其使用方法和用途 | |
MY135776A (en) | PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
WO2007030780A3 (fr) | Agents antitumoraux | |
EP2470531A1 (fr) | Méthylpyrrolopyrimidine-carboxamides | |
JPWO2020016129A5 (fr) | ||
RU2021103602A (ru) | Производные тирозинамида в качестве ингибиторов rho-киназы | |
CA3126689A1 (fr) | Compose heteroaryle a noyau fusionne utilise en tant qu'inhibiteur d'alk4/5 | |
RU2007114284A (ru) | Производное имидазола |